
|Articles|April 4, 2016
Disease Interception and the US National Cancer Moonshot
Author(s)DIA
Advertisement
In the US, patients, caregivers and advocates, drug developers and the FDA have moved towards a patient-centered approach to drug development. The National Cancer Moonshot, a task force led by Vice President Joseph Biden, includes this patient-centric strategy in its agenda: Seeking to facilitate collaborations with researchers, doctors, philanthropies, patients, patient advocates, and biotechnology and pharmaceutical companies to accelerate the early detection and treatment of cancer, its goal is a decade’s worth of advances in five years.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive
2
U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
Navigating PBM Pitfalls: Protecting Revenue in a Complex Rebate Landscape
5




